GlassScriptPhysician profile
Adam N Rhoades
NPI 1659519692
$4,615.25
in general payments reported to CMS, 2019-2025
30 companies · $704 in 2025
The $704 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $804 · 2022: $841 · 2023: $1,008 · 2024: $1,258 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,924 · Education: $45.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.43 |
| Education | $45.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $583.11 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Horizon Therapeutics Plc | $455.40 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $439.01 | 2021-2025 | Jynarque, Rexulti |
| Astrazeneca Pharmaceuticals LP | $422.15 | 2021-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $355.37 | 2021-2025 | Veltassa, Korsuva |
| Daiichi Sankyo INC. | $323.81 | 2021-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $239.43 | 2022-2025 | Lupkynis |
| Ardelyx, INC. | $224.44 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Travere Therapeutics, INC. | $202.98 | 2021-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $188.90 | 2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $171.74 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $161.97 | 2023-2025 | |
| Akebia Therapeutics INC | $111.20 | 2021-2024 | Auryxia, Vafseo |
| Xeris Pharmaceuticals, INC. | $99.05 | 2022-2024 | Keveyis |
| Baxter Healthcare | $92.22 | 2023 | Renal - Pd |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $82.59 | 2022-2023 | Benlysta |
| Novo Nordisk INC | $76.65 | 2025 | Wegovy |
| Fresenius USA Marketing, INC. | $45.33 | 2021-2024 | Velphoro |
| Alexion Pharmaceuticals, INC. | $45.13 | 2021-2023 | Ultomiris |
| Calliditas Therapeutics US INC. | $44.67 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $43.81 | 2024 | Jardiance |
| Abbvie INC. | $41.18 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.22 | 2021 | |
| Scpharmaceuticals INC. | $24.64 | 2023 | |
| Alnylam Pharmaceuticals INC. | $22.99 | 2023 | Oxlumo |
| Opko Pharmaceuticals, LLC | $22.79 | 2021 | |
| Abbott Laboratories | $19.02 | 2025 | Freestyle Libre 3 |
| Fresenius USA Manufacturing, INC. | $17.76 | 2025 | |
| Exact Sciences Corporation | $17.51 | 2025 | The Cologuard Plus Collection Kit |
| Apellis Pharmaceuticals, INC. | $14.18 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rhoades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.